The four major companies in the orthopedics space – Johnson & Johnson, Smith & Nephew PLC, Stryker Corp. and Zimmer Biomet Holdings Inc. – have all seen significant reductions in first-quarter revenues due to the delay of elective procedures as hospitals focused on treating COVID-19 patients.
With many US states taking steps to resume outpatient and inpatient elective surgeries under President Donald Trump’s three-part plan to reopen the country, companies are hoping to ramp up...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?